SOURCE: Afaxys Pharmaceuticals

July 01, 2013 16:58 ET

Chateal Coverage Expands Significantly

Afaxys Pharmaceuticals' New Oral Contraceptive Covered by FPACT/Medi-Cal and Pennsylvania Medicaid

CHARLESTON, SC--(Marketwired - Jul 1, 2013) -  Afaxys Pharmaceuticals' oral contraceptive, CHATEAL® \shah•TEEL\ (Levonorgestrel and Ethinyl Estradiol tablets USP, 0.15 mg/0.03mg) is now covered by California's Family Planning, Access, Care and Treatment (Family PACT) program. The purpose of FPACT ( is to provide comprehensive family planning services to low-income men and women; the program serves 18.8 million individuals of child-bearing age.

The Chateal inclusion in FPACT coverage marks a major milestone for Afaxys Pharmaceuticals (, a division of Afaxys Inc., which has a stated mission of serving public health and safety net family planning providers who have long been buffeted by soaring prices and product shortages.

Afaxys also received notification that Pennsylvania Medicaid will add Chateal to the Preferred Drug List (PDL) starting July 1. This makes Chateal reimbursable on all 50 states' fee for service Medicaid plans.

Available only to the public health sector (including family planning clinics; college and university health centers; community health centers; and city, county, state and federal facilities), and authorized, non-retail prescribers, this Afaxys Pharmaceuticals product is now covered under all fee for service Medicaid plans and most commercial managed-care formularies.

Afaxys Pharmaceuticals aims to continue to provide high-priority contraceptive products, like CHATEAL, at low costs to public health family planning providers. As additional contraceptive products become available the company will extend its core contraceptive formulary, allowing health centers to decrease high inventory costs by purchasing fewer products while still meeting their patients' needs.

Note: This press release was issued in the United States and is intended as reference information for U.S. journalists and customers. The information contained in this Afaxys press release is accurate at the time of issuance, and the company assumes no responsibility for updating the information to reflect subsequent developments.

Contact Information